Lipika Goyal, MD, of Massachusetts General Hospital, discusses phase II results of the FOENIX-CCA2 trial, which explored the clinical benefit of futibatinib, an FGFR1–4 inhibitor, tested in patients with intrahepatic cholangiocarcinoma that harbored FGFR2 gene fusions or other rearrangements (Abstract CT010).
Brian I. Rini, MD, of Vanderbilt University, discusses the IMmotion151 trial results on overall survival and the association of gene expression and clinical outcomes with ate...
Matthew J. Matasar, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III results of the CHRONOS-3 trial, which showed that copanlisib plus rituximab led to a 48...
Vivek Subbiah, MD, of The University of Texas MD Anderson Cancer Center, discusses data on selpercatinib that...
Rita Nanda, MD, of the University of Chicago, discusses the latest data on novel treatment strategies for triple-negative breast cancer, including immune checkpoint, PARP, an...
Katelyn T. Byrne, PhD, of the Perelman School of Medicine at the University of Pennsylvania, discusses the first in-depth analysis of the impact of selicrelumab, an anti-CD40...
